Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors

OBJECTIVE: To evaluate effects of the anti-interleukin-6 receptor monoclonal antibody sarilumab administered with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) on patient-reported outcomes (PROs) in the TARGET trial in patients with rheumatoid arthritis (RA) with inadequate...

Descripción completa

Detalles Bibliográficos
Autores principales: Strand, Vibeke, Reaney, Matthew, Chen, Chieh-I, Proudfoot, Clare W J, Guillonneau, Sophie, Bauer, Deborah, Mangan, Erin, Graham, Neil M H, van Hoogstraten, Hubert, Lin, Yong, Pacheco-Tena, César, Fleischmann, Roy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5353328/
https://www.ncbi.nlm.nih.gov/pubmed/28326189
http://dx.doi.org/10.1136/rmdopen-2016-000416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5353328/
https://www.ncbi.nlm.nih.gov/pubmed/28326189
http://dx.doi.org/10.1136/rmdopen-2016-000416

Ejemplares similares